SCHEMBL25426159

SCHEMBL25426159

CCN(C)C(=O)C(=O)c1c[nH]c2ccc(C)c(OCc3ccccc3)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ MDH2 P40926 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ JAK2 O60674 1/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ LTB4R Q15722 1/20 0.36
▸ LTB4R2 Q9NPC1 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ TRPM8 Q7Z2W7 2/20 0.36
▸ PTGER1 P34995 1/20 0.36
▸ PTGER4 P35408 1/20 0.36
▸ PTGER3 P43115 1/20 0.36
▸ PTGER2 P43116 1/20 0.36
▸ HTR1D P28221 2/20 0.36
▸ GABRA1 P14867 1/20 0.36
▸ GABRB1 P18505 1/20 0.36
▸ GABRA3 P34903 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25748242 0.92 HTR2A (0.39) PTPN1SMN1; SMN2ALDH1A1HPGDMDH2
SCHEMBL25748258 0.91 PTPN1 (0.39) PTPN1SMN1; SMN2ALDH1A1HPGDMDH2
SCHEMBL25748246 0.87 PTPN1 (0.38) PTPN1SMN1; SMN2ALDH1A1HPGDMDH2
SCHEMBL25748279 0.87 HTR1D (0.39) PTPN1SMN1; SMN2ALDH1A1HPGDMDH2
SCHEMBL31077657 0.85 PTPN1 (0.38) PTPN1SMN1; SMN2ALDH1A1HPGDMDH2
SCHEMBL25748229 0.85 SLC6A4 (0.39) SMN1; SMN2ALDH1A1HPGDMDH2HTR2A
SCHEMBL25748215 0.84 PTPN1 (0.42) PTPN1SMN1; SMN2ALDH1A1HPGDMDH2
SCHEMBL25436274 0.83 ALDH1A1 (0.38) ALDH1A1HTR1DMEN1KMT2AMAPT
SCHEMBL23805237 0.83 HTR2A (0.54) SMN1; SMN2ALDH1A1HPGDMDH2HTR2A
SCHEMBL25748377 0.81 SMN1; SMN2 (0.41) PTPN1SMN1; SMN2HPGDHTR2AJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250101038-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-03-27 — — US disclosed
EP-4452937-A1 COMPOUNDS Psylo Pty Ltd (AU) 2024-10-30 — — EP disclosed
CN-118715204-A Compounds of formula (I) 普赛洛私人有限公司 2024-09-27 — — CN disclosed
WO-2023115166-A1 COMPOUNDS Psylo Pty Ltd (AU) 2023-06-29 — — WO disclosed
WO-2023115166-A1 COMPOUNDS Psylo Pty Ltd (AU) 2023-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101038-A1 COMPOUNDS NLN, SLC18A2, PYGB PTPN1 4226/4885SMN1; SMN2 138/4885ALDH1A1 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback